Destiny Pharma has announced new data on one of its compounds, XF-70, which has demonstrated potency in an in vivo model of ringworm, a common fungal skin infection, which affects up to one in four people worldwide. Ringworm is caused by a class of fungi called… Read More
Data generated from a C. difficile infection (CDI) model study on the ability of M3 (NTCD-M3), a non-toxigenic C. difficile strain, shows successful gut colonisation following administration of fidaxomicin and has been peer-reviewed and published in Microbiology Spectrum. The paper by Destiny Pharma, a UK-based clinical stage biotechnology company focused… Read More
Under a new agreement, Destiny Pharma and Sebela Pharmaceuticals will co-develop NTCD-M3, Destiny’s lead asset for the prevention of Clostridioides difficile infection (CDI) recurrence. It is anticipated that Sebela will lead and finance the future clinical development and commercialisation activities of NTCD-M3 in North America. … Read More
